Project Grant R01CA293922
Award Date
9/15/24
Completion Date
8/31/29
Dollars Obligated
$1.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $1,313,806.00 in funding from August 13, 2024 through July 31, 2029. The grant supports the development and clinical translation of mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapies for solid tumors. Key objectives include: Elucidating the mechanisms by which the KITV costimulatory domain enhances CAR T-cell...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to harness B cells after stem cell transplant to produce novel chimeric antigen receptor T-cells (CAR-Ts) for treating hematological malignancies. The $415,257 award to Duke University, a leading research institution, will fund research to clone antibody-producing B cells with tumor-binding potential after hematopoietic stem cell transplantation. The goal is to engineer less toxic and...
The National Cancer Institute (NCI) awarded a Project Grant, CFDA 93.395 "Cancer Treatment Research", to the University of North Carolina at Chapel Hill (UNC-CH) in the amount of $627,456 on December 1, 2024. The purpose of this 5-year grant is to conduct a Phase I clinical trial evaluating the safety and efficacy of a CSPG4-targeted CAR-T cell therapy for the treatment of head and neck squamous cell carcinoma (HNSCC) that is refractory to platinum-based chemotherapy and PD-1...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program 93.395 Cancer Treatment Research (CFDA 93.395), is funding the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The $402,600 award, granted on Apr 3, 2025, supports research by the Sloan-Kettering Institute for Cancer Research to: (1) test the efficacy and...
The federal Project Grant award of $4,029,612 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the "INFLUENCE TRIAL: IMPROVING EVENT-FREE SURVIVAL BY OPTIMIZING FLUDARABINE EXPOSURE DURING LYMPHODEPLETION FOR CAR T CELL THERAPY" at the Sloan-Kettering Institute for Cancer Research in New York. This grant aims to optimize fludarabine exposure during lymphodepletion to improve event-free survival for patients receiving CAR T-cell...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
The National Cancer Institute (NCI), through the Cancer Treatment Research program (CFDA 93.395), awarded a $1,999,703 project grant to March Biosciences Inc. to develop dual-targeting allogeneic chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The 2-year project aims to engineer partially-matched donor-derived CAR-T cells targeting both CD5 and CD7 antigens, which are expressed in...